Leismania donovani is a parasite responsible for a fatal tropical disease – visceral leishmaniasis. Transmitted to humans essentially by bites from infected sandflies or mosquitoes, leishmaniasis can be contracted in many tropical and subtropical countries as well as around the perimeter of the Mediterranean.

The Transleish project will perfect new drugs to combat leishmaniasis using marine-sourced molecules from different families of corals, sponges and sea squirts.

The project will seek to identify new compounds and to evaluate the active proportion in the organism in relation to the amount absorbed. The project will involve medically analysing these active compounds to develop and apply new strategies for protein analysis.

These protein kinases will be validated as potential target treatments using biochemical and genetic approaches.

  • - ManRos Therapeutics, Roscoff
Research centers
  • - Institut Pasteur, Parasitologie moléculaire et signalisation, Paris  [Project Developer]
  • - Station Biologique de Roscoff, Protein Phosphorylation and Human Disease, Roscoff
- Agence Nationale de la Recherche
Overall budget
2 861 K€